

Instance: composition-en-1f037c7eeed99a83d34b7e97df29f3bf
InstanceOf: CompositionUvEpi
Title: "Composition for faslodex Package Leaflet"
Description:  "Composition for faslodex Package Leaflet"
Usage: #example

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mock)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - faslodex"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Faslodex is and what it is used for</li>
<li>What you need to know before you use Faslodex</li>
<li>How to use Faslodex</li>
<li>Possible side effects</li>
<li>How to store Faslodex</li>
<li>Contents of the pack and other information</li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What faslodex is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What faslodex is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Faslodex contains the active substance fulvestrant, which belongs to the group of estrogen blockers. 
Estrogens, a type of female sex hormones, can in some cases be involved in the growth of breast 
cancer.
Faslodex is used either: </p>
<p>alone, to treat postmenopausal women with a type of breast cancer called estrogen receptor 
positive breast cancer that is locally advanced or has spread to other parts of the body 
(metastatic), or</p>
<p>in combination with palbociclib to treat women with a type of breast cancer called hormone 
receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, that is
locally advanced or has spread to other parts of the body (metastatic). Women who have not 
reached menopause will also be treated with a medicine called a luteinizing hormone releasing 
hormone (LHRH) agonist.
When Faslodex is given in combination with palbociclib, it is important that you also read the package 
leaflet for palbociclib. If you have any questions about palbociclib, please ask your doctor.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take faslodex"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take faslodex"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Do not use Faslodex:</h2>
<p>if you are allergic to fulvestrant or to any of the other ingredients of this medicine (listed in 
section 6)
-
if you are pregnant or breast-feeding
-
if you have severe liver problems
Warnings and precautions
Talk to your doctor or pharmacist or nurse before using Faslodex if any of these apply to you:
-
kidney or liver problems
-
low numbers of platelets (which help blood clotting) or bleeding disorders 
-
previous problems with blood clots
-
osteoporosis (loss of bone density)
-
alcoholism
Children and adolescents
Faslodex is not indicated in children and adolescents under 18 years.
Other medicines and Faslodex
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines.
In particular, you should tell your doctor if you are using anticoagulants (medicines to prevent blood 
clots).
Pregnancy and breast-feeding
You must not use Faslodex if you are pregnant. If you can become pregnant, you should use effective 
contraception while you are being treated with Faslodex and for 2 years after your last dose.
You must not breast-feed while on treatment with Faslodex.
Driving and using machines
Faslodex is not expected to affect your ability to drive or use machines. However, if you feel tired after 
treatment do not drive or use machines.
Faslodex contains 10% w/v ethanol (alcohol), i.e. up to 500 mg per injection, equivalent to 10 ml 
beer or 4 ml wine.
Harmful for those suffering from alcoholism.
To be taken into account in high-risk groups such as patients with liver disease, or epilepsy.
Faslodex contains 500 mg benzyl alcohol per injection, equivalent to 100 mg/ml.
Benzyl alcohol may cause allergic reactions.
Faslodex contains 750 mg benzyl benzoate per injection, equivalent to 150 mg/ml.</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take faslodex"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take faslodex"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or 
pharmacist if you are not sure.
The recommended dose is 500 mg fulvestrant (two 250 mg/5 ml injections) given once a month, with 
an additional 500 mg dose given 2 weeks after the initial dose.
Your doctor or nurse will give you Faslodex as a slow intramuscular injection, one into each of your 
buttocks.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.
You may need immediate medical treatment if you experience any of the following side effects:</p>
<p>Allergic (hypersensitivity) reactions, including swelling of the face, lips, tongue and/or throat
that may be signs of anaphylactic reactions</p>
<p>Thromboembolism (increased risk of blood clots)*<br />
Inflammation of the liver (hepatitis)</p>
<p>Liver failure
Tell your doctor, pharmacist, or nurse if you notice any of the following side effects:
Very common side effects (may affect more than 1 in 10 people)</p>
<p>Injection site reactions, such as pain and/or inflammation</p>
<p>Abnormal levels of liver enzymes (in blood tests)*<br />
Nausea (feeling sick)</p>
<p>Weakness, tiredness*<br />
Joint and musculoskeletal pain</p>
<p>Hot flushes</p>
<p>Skin rash</p>
<p>Allergic (hypersensitivity) reactions, including swelling of the face, lips, tongue and/or throat
All other side effects:
Common side effects (may affect up to 1 in 10 people)</p>
<p>Headache</p>
<p>Vomiting, diarrhoea, or loss of appetite*<br />
Urinary tract infections</p>
<p>Back pain*<br />
Increase of bilirubin (bile pigment produced by the liver)</p>
<p>Thromboembolism (increased risk of blood clots)*<br />
Decreased levels of platelets (thrombocytopenia)</p>
<p>Vaginal bleeding</p>
<p>Lower back pain irradiating to leg on one side (sciatica)</p>
<p>Sudden weakness, numbness, tingling, or loss of movement in your leg, especially on only one
side of your body, sudden problems with walking or balance (peripheral neuropathy)
Uncommon side effects (may affect up to 1 in 100 people)</p>
<p>Thick, whitish vaginal discharge and candidiasis (infection)</p>
<p>Bruising and bleeding at the site of injection</p>
<p>Increase of gamma-GT, a liver enzyme seen in a blood test</p>
<p>Inflammation of the liver (hepatitis)</p>
<p>Liver failure</p>
<p>Numbness, tingling and pain</p>
<p>Anaphylactic reactions
* Includes side effects for which the exact role of Faslodex cannot be assessed due to the underlying 
disease.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store faslodex"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store faslodex"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton or syringe labels after EXP. 
The expiry date refers to the last day of that month.
Store and transport in a refrigerator (2 C - 8 C).
Temperature excursions outside 2 C - 8 C should be limited. This includes avoiding storage at 
temperatures exceeding 30 C, and not exceeding a 28-day period where the average storage 
temperature for the product is below 25 C (but above 2 C - 8 C). After temperature excursions, the 
product should be returned immediately to the recommended storage conditions (store and transport in 
a refrigerator 2 C - 8 C). Temperature excursions have a cumulative effect on the product quality and 
the 28-day time period must not be exceeded over the duration of the 4-year shelf life of Faslodex. 
Exposure to temperatures below 2 C will not damage the product providing it is not stored below
-20 C.
Keep the pre-filled syringe in the original package, in order to protect from light.
Your healthcare professional will be responsible for the correct storage, use and disposal of Faslodex.
This medicine may pose a risk to the aquatic environment. Do not throw away any medicines via 
wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. 
These measures will help protect the environment.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>What Faslodex contains</h2>
<h2>The active substance is fulvestrant. Each pre-filled syringe (5 ml) contains 250 mg fulvestrant.</h2>
<p>The other ingredients (excipients) are ethanol (96 per cent), benzyl alcohol, benzyl benzoate and 
castor oil refined.
What Faslodex looks like and contents of the pack
Faslodex is a clear, colourless to yellow, viscous solution in a pre-filled syringe fitted with a 
tamper-evident closure, containing 5 ml solution for injection. Two syringes must be administered to 
receive the 500 mg recommended monthly dose.
Faslodex has 2 pack presentations, either a pack containing 1 glass pre-filled syringe or a pack 
containing 2 glass pre-filled syringes. Safety needles (BD SafetyGlide) for connection to each barrel 
are also provided.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
AstraZeneca AB
SE-151 85 S dert lje
Sweden
Manufacturer
AstraZeneca AB
Global External Sourcing (GES)
Astraall n
G rtunaporten 
SE-151 85 S dert lje
Sweden
AstraZeneca UK Limited
Silk Road Business Park
Macclesfield
Cheshire
SK10 2NA
United Kingdom
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder:
Belgi /Belgique/Belgien
AstraZeneca S.A./N.V.
Tel: +32 2 370 48 Lietuva
UAB AstraZeneca Lietuva
Tel: +370 5 2660 </p>
<p>.: +359 24455Luxembourg/Luxemburg
AstraZeneca S.A./N.V.
T l/Tel: +32 2 370 48  esk  republika
AstraZeneca Czech Republic s.r.o.
Tel: +420 222 807 Magyarorsz g
AstraZeneca Kft
Tel: +36 1 883 6Danmark
AstraZeneca A/S
Tlf: +45 43 66 64 Malta
Associated Drug Co. Ltd
Tel: +356 2277 8Deutschland
AstraZeneca GmbH
Tel: +49 40 809034Nederland
AstraZeneca BV
Tel: +31 79 363 2Eesti
AstraZeneca 
Tel: +372 6549 Norge
AstraZeneca AS
Tlf: +47 21 00 64<br />
AstraZeneca A.E.
 : + 30 210 6871 sterreich
AstraZeneca  sterreich GmbH
Tel: +43 1 711 31 0
Espa a
AstraZeneca Farmac utica Spain, S.A.
Tel: +34 91 301 91 Polska
AstraZeneca Pharma Poland Sp. z o.o.
Tel.: +48 22 245 73 France
AstraZeneca
T l: +33 1 41 29 40 Portugal
AstraZeneca Produtos Farmac uticos, Lda.
Tel: +351 21 434 61 Hrvatska 
AstraZeneca d.o.o.
Tel: +385 1 4628 Rom nia
AstraZeneca Pharma SRL
Tel: +40 21 317 60 Ireland
AstraZeneca Pharmaceuticals (Ireland) DAC
Tel: +353 1609 7Slovenija
AstraZeneca UK Limited
Tel: +386 1 51 35  sland
Slovensk  republika
Vistor hf.
S mi: +354 535 7AstraZeneca AB, o.z.
Tel: +421 2 5737 7Italia
AstraZeneca S.p.A.
Tel: +39 02 00704Suomi/Finland
AstraZeneca Oy
Puh/Tel: +358 10 23  </p>
<p>: +357 22490Sverige
AstraZeneca AB
Tel: +46 8 553 26 Latvija
SIA AstraZeneca Latvija
Tel: +371 67377United Kingdom (Northern Ireland)
AstraZeneca UK Ltd
Tel: +44 1582 836 This leaflet was last revised in
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      

